Volume 565 Issue 7738, 10 January 2019
Letter | 19 December 2018
Actively personalized vaccination trial for newly diagnosed glioblastoma
In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.
Norbert Hilf, Sabrina Kuttruff-Coqui […] & Wolfgang Wick